DBXO 1
Alternative Names: DBXO-1Latest Information Update: 28 Apr 2026
At a glance
- Originator Deck Bio
- Class Antineoplastics; Bispecific antibodies; Immunoglobulin Fc fragments; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gastric cancer; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours
Most Recent Events
- 20 Apr 2026 Preclinical trials in Solid tumours in USA (Parenteral) before April 2026
- 20 Apr 2026 Pharmacodynamic and pharmacokinetic data from a preclinical trial in Solid tumour released by Deck Bio
- 09 Apr 2026 Preclinical trials in Gastric cancer in USA (Parenteral) before April 2026 (Deck Bio pipeline, April 2026)